Exhibit 99.1 Barclays PLC This exhibit includes portions from the previously published Results Announcement of Barclays PLC relating to the nine months ended 30 September 2024, as amended in part to comply with the requirements of Regulation G and Item 10(e) of Regulation S-K promulgated by the US Securities and Exchange Commission (SEC), including the reconciliation of certain financial information to comparable measures prepared in accordance with International Financial Reporting Standards (IFRS). The pu ...

Barclays PLC (NYSE:BCS) Q3 2024 Earnings Conference Call October 24, 2024 4:30 AM ET Company Participants C.S. Venkatakrishnan - Group Chief Executive Angela Cross - Group Finance Director Conference Call Participants Jason Napier - UBS Benjamin Toms - RBC Chris Cant - Autonomous Edward Firth - KBW Guy Stebbings - BNP Paribas Amit Goel - Mediobanca Chris Hallam - Goldman Sachs Alvaro Serrano - Morgan Stanley Robin Down - HSBC Perlie Mong - Bank of America Merrill Lynch Andrew Coombs - Citi Group Operator We ...

Barclays’ (BCS) third-quarter 2024 net income attributable to ordinary equity holders of £1.56 billion ($2.03 billion) grew 23% year over year.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Shares of BCS on NYSE gained 4% in pre-market trading as profit increased. Investors also cheered an upward tweak in net interest income (NII) 2024 guidance.An increase in revenues (driven by solid investment banking performance), stable operating expenses (showing the success of cost-efficiency ...

LONDON — British bank Barclays on Thursday reported £1.6 billion ($2 billion) net profit attributable to shareholders for the third quarter, beating expectations.The result compared with the £1.17 billion net profit forecast in an LSEG poll of analysts, and was 23% higher than the same period in 2023.Revenue for the period came in at £6.5 billion, slightly ahead of a forecast of £6.39 billion.The lender's return on tangible equity rose to 12.3% from 9.9% in the second quarter, as its CET1 ratio — a measure ...

Barclays US Consumer Bank will become the exclusive issuer of General Motors' GM Rewards Mastercard and GM Business Mastercard in the United States in the summer of 2025 and will acquire the card program's receivables from the current issuer — Goldman Sachs — next year. The bank and the automaker announced their new long-term partnership agreement in a Monday (Oct. 14) press release. "As a leading and experienced player in the U.S. partner card market with a winning formula for growing partner programs, we ...

Barclays upgraded CVS Health Inc CVS on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by share gains, with further upside potential from CostVantage.Despite macroeconomic pressures impacting the retail pharmacy sector, the analyst writes that CVS has shown resilience thanks to its diversified business model.Also Read: CVS, UnitedHealth Request FTC Chair Recusal Amid Ongoing Pharmacy Benefit Managers Lawsuit.This has allowed the company to mitigate some of these challenges and c ...

Core Insights - Robinhood Markets announced its first investor day scheduled for December 4, where it will discuss its long-term vision and strategies to enhance customer and shareholder value [1] - Barclays raised its price target for Robinhood from $20 to $23, citing ongoing business momentum and expected growth in transaction revenues [2] - Shares of Robinhood have nearly doubled in 2024, reflecting strong market performance and investor interest [1][2] Company Developments - The investor day will take place in New York City, allowing executives to engage with investors and analysts [1] - Barclays analysts anticipate that transaction revenues will exceed Wall Street estimates by 5% in the upcoming quarters [2] - CEO Vlad Tenev is expected to introduce new products at the upcoming "HOOD Summit" on October 16 [2] Market Performance - Robinhood's stock experienced an approximately 8% increase on the day of the announcement, contributing to its year-to-date gains [2] - The stock price reached $25.01, reflecting a 7.23% increase on the trading day [3]

Key TakeawaysStellantis reported U.S. sales slumped 20% year-over-year in the third quarter as all of its brands except Fiat posted declines.The automaker will continue to offer incentives begun in the beginning of the quarter through the rest of the year.Barclays analysts downgraded the stock, saying they see no sign of recovery until the first half of next year at the earliest. Stellantis (STLA) shares fell Thursday after the automaker's U.S. unit reported a big drop in sales as all but one of its brands ...

Core Insights - Perimeter Medical Imaging AI, Inc. has developed the Perimeter B-Series OCT system, which integrates AI with optical coherence tomography for margin assessment during breast-conserving surgeries, aiming to reduce high reoperation rates associated with breast cancer surgeries [1][4] Group 1: Clinical Trial and Results - A pivotal study has completed patient enrollment, involving approximately 530 women undergoing breast-conserving surgery for Stage 0-III invasive ductal carcinoma [2][3] - The primary endpoint of the trial is to evaluate the occurrence of unaddressed positive margins, with a within-subject analysis planned [3] - Results from the pivotal trial are expected in Q4-2024, which could support a submission to the FDA in 2025 [1][4] Group 2: Market Implications - If successful, the B-Series OCT system could receive the first-ever marketing clearance for specific use in breast tissue and margin evaluation, representing a significant milestone for Perimeter's business [1][4] - The technology aims to empower surgeons with real-time intraoperative tools to improve margin assessment and potentially lower re-excision rates, setting a new standard in specimen imaging technology [4] Group 3: Financial and Operational Context - The company has received a grant of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas to support the clinical trial [6] - The Perimeter S-Series OCT system is already FDA-cleared for general indications, while the B-Series is currently investigational and not available for sale in the U.S. [6][7]

Investors interested in stocks from the Banks - Foreign sector have probably already heard of Barclays (BCS) and Nordea Bank AB (NRDBY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy that target ...